US6448077B1ExpiredUtility
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
Est. expiryFeb 10, 2014(expired)· nominal 20-yr term from priority
C07K 2317/77A61K 38/00C07K 2317/73C07K 2317/24C07K 2319/00C07K 14/71C07K 2317/74C07K 16/2863
89
PatentIndex Score
53
Cited by
23
References
38
Claims
Abstract
Chimeric and humanized monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A monoclonal antibody that specifically binds to an extracellular domain of a flt-1 receptor and neutralizes activation of the receptor.
2. An antibody of claim 1 , wherein the flt-1 receptor is mammalian.
3. An antibody of claim 1 , wherein the flt-1 receptor is human.
4. A cell line producing a monoclonal antibody of claim 1 .
5. A cell line producing the antibody of claim 3 .
6. A composition comprising the antibody of claim 1 or claim 3 and a pharmaceutically acceptable carrier.
7. The composition of claim 6 further comprising a chemotherapeutic agent and a pharmaceutically acceptable carrier.
8. A monoclonal antibody that specifically binds to an extracellular domain of a flt-1 receptor and reduces tumor growth.
9. An antibody of claim 8 , wherein the flt-1 receptor is mammalian.
10. An antibody of claim 8 , wherein the flt-1 receptor is human.
11. A cell line producing a monoclonal antibody of claim 8 .
12. A cell line producing the antibody of claim 10 .
13. A composition comprising the antibody of claim 8 or claim 10 and a pharmaceutically acceptable carrier.
14. The composition of claim 13 further comprising a chemotherapeutic agent and a pharmaceutically acceptable carrier.
15. A humanized monoclonal antibody that specifically binds to an extracellular domain of a flt-1 receptor and reduces tumor growth.
16. An antibody of claim 15 , wherein the flt-1 receptor is mammalian.
17. An antibody of claim 15 , wherein the flt-1 receptor is human.
18. A cell line producing the humanized monoclonal antibody of claim 15 .
19. A cell line producing the antibody of claim 17 .
20. A composition comprising the antibody of claim 15 or claim 17 and a pharmaceutically acceptable carrier.
21. The composition of claim 20 further comprising a chemotherapeutic agent and a pharmaceutically acceptable carrier.
22. A humanized monoclonal antibody that specifically binds to an extracellular domain of a flt-1 receptor and reduces tumor growth.
23. An antibody of claim 22 , wherein the flt-1 receptor is mammalian.
24. An antibody of claim 22 , wherein the flt-1 receptor is human.
25. A cell line producing the humanized monoclonal antibody of claim 22 .
26. A cell line producing the antibody of claim 24 .
27. A composition comprising the antibody of claim 22 or claim 24 and a pharmaceutically acceptable carrier.
28. The composition of claim 27 further comprising a chemotherapeutic agent and a pharmaceutically acceptable carrier.
29. An antibody of claim 1 or claim 8 , wherein the antibody is chimerized.
30. A cell line of claim 4 or claim 11 , wherein the monoclonal antibody is chimerized.
31. A monoclonal antibody that specifically binds to an extracellular domain of a flt-1 receptor and inhibits angiogenesis.
32. A monoclonal antibody of claim 31 , wherein the flt-1 receptor is mammalian.
33. A monoclonal antibody of claim 31 , wherein the flt-1 receptor is human.
34. A monoclonal antibody of claim 31 , wherein the antibody is chimerized.
35. A monoclonal antibody of claim 31 , wherein the monoclonal antibody is humanized.
36. A cell line producing a monoclonal antibody of claim 31 .
37. A composition comprising an antibody of claim 31 and a pharmaceutically acceptable carrier.
38. A composition of claim 37 further comprising a chemotherpeutic agent.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.